Recro Pharma Inc. (United States) is listed on the Nasdaq and has a market capitalization of $40.62 Millions, with shareholders equity totaling $39.16 Millions.
The company employs approximately 185 people and operates in the Health Care sector, within the Biotechnology industry.
Over the past 12 months, Recro Pharma Inc. reported $61.53 Millions in revenue, generating net income of $-8.87 Millions.
Key financial metrics include a P/E ratio of -4.58, a price-to-book (P/B) ratio of 1.04, and a trailing twelve-month dividend yield of 0.00%.
The company trades under the ticker REPH.